TNSN97001A1 - CONTROLLED RELEASE PHARMACEUTICAL PEARLS CONTAINING FUROSEMIDE, AND A COMPOSITION MADE WITH SAID PEARLS. - Google Patents

CONTROLLED RELEASE PHARMACEUTICAL PEARLS CONTAINING FUROSEMIDE, AND A COMPOSITION MADE WITH SAID PEARLS.

Info

Publication number
TNSN97001A1
TNSN97001A1 TNTNSN97001A TNSN97001A TNSN97001A1 TN SN97001 A1 TNSN97001 A1 TN SN97001A1 TN TNSN97001 A TNTNSN97001 A TN TNSN97001A TN SN97001 A TNSN97001 A TN SN97001A TN SN97001 A1 TNSN97001 A1 TN SN97001A1
Authority
TN
Tunisia
Prior art keywords
pearls
controlled release
minutes
furosemide
release pharmaceutical
Prior art date
Application number
TNTNSN97001A
Other languages
French (fr)
Inventor
Hans Arwidsson
Maria Eriksson
Lars Stubberud
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Publication of TNSN97001A1 publication Critical patent/TNSN97001A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRESENTE INVENTION SE RAPPORTE A LA FABRICATION DE PERLES A LIBERATION CONTROLEE COMPRENANT UN NOYAU EN MATIERE INERTE SOLUBLE OU INSOLUBLE POURVU A UNE COUCHE DE FUROSEMIDE DISPERSE DANS UN POLYMERE HYDROPHILE ET REVETU D'UNE MEMBRANE EXTERIEURE SPECIFIQUE POUR LA LIBERATION CONTROLEE DU FUROSEMIDE, CETTE MEMBRANE COMPRENANT 1- UN PRODUIT FILMOGENE SELECTIONNE A PARTIR D'ENZTHYLE CELLULOSE ET DE COPOLYMERISATS D'ESTER D'ACIDE ACRYLIQUE ET METHACRYLIQUE ET 2- AU MOINS UN POLYMERE HYDROPHILE SELECTIONNE A PARTIR DE POLYVINYLPYRROLIDONE, HYDROXYPROPYLE CELLULOSE ET POLYALKYLENE GLYCOL ; ET OU LA QUANTITE DE LA MEMBRANE EXTERIEURE SE SITUE ENTRE 35 ET 65 % PONDERAL DU POIDS DU NOYAU REVETU SEC, ET CARACTERISE PAR LE FAIT QUE LE PROFIL DE LIBERATION DU FUROSEMIDE N'EST PAS SUPERIEUR A 30 % APRES 60 MINUTES, A 44% APRES 120 MINUTES, ET EST SUPERIEUR A 80 % APRES 360 MINUTES. LA PRESENTE INVENTION SE RAPPORTE EGALEMENT A UN PROCEDE POUR LA PREPARATION DES DITES PERLES A LIBERATION CONTROLEE, A UNE COMPOSITION PHARMACEUTIQUE COMPRENANT LES DITES PERLES ET A L'EMPLOI DE CES PERLES POUR LE TRAITEMENT DES MALADIES CARDIOVASCULAIRES TELLES QUE HYPERTENSION, INSUFFISANCE CARDIAQUE CONGESTIVE, ET OEDEME.THIS INVENTION RELATES TO THE MANUFACTURE OF CONTROLLED RELEASE PEARLS COMPRISING A CORE OF SOLUBLE OR INSOLUBLE INERT MATERIAL PROVIDED WITH A LAYER OF FUROSEMIDE DISPERSE IN A HYDROPHILIC POLYMER COATED WITH AN EXTERNAL MEMBRANE SPECIFICALLY FOR LIBERATION. COMPRISING 1- A FILM-FORMING PRODUCT SELECTED FROM ENZTHYL CELLULOSE AND ESTER COPOLYMERISATES OF ACRYLIC AND METHACRYLIC ACID AND 2- AT LEAST ONE HYDROPHILIC POLYMER SELECTED FROM POLYVINYLPYRROLIDONE AND POLYLYLYCLYPROPYLENE AND WHERE THE QUANTITY OF THE OUTER MEMBRANE IS BETWEEN 35 AND 65% PONDERAL OF THE WEIGHT OF THE DRY COATED CORE, AND CHARACTERIZED BY THE FACT THAT THE RELEASE PROFILE OF FUROSEMIDE IS NOT MORE THAN 30% AFTER 60 MINUTES, AT 44% AFTER 120 MINUTES, AND IS MORE THAN 80% AFTER 360 MINUTES. THIS INVENTION ALSO RELATES TO A PROCESS FOR THE PREPARATION OF SAID CONTROLLED RELEASE PEARLS, A PHARMACEUTICAL COMPOSITION COMPRISING SAID PEARLS AND THE USE OF SUCH PEARLS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES SUCH AS HYPERTENSION, HEART FAILURE EDEMA.

TNTNSN97001A 1996-01-05 1997-01-03 CONTROLLED RELEASE PHARMACEUTICAL PEARLS CONTAINING FUROSEMIDE, AND A COMPOSITION MADE WITH SAID PEARLS. TNSN97001A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9600046A SE9600046D0 (en) 1996-01-05 1996-01-05 New pharmaceutical formulation

Publications (1)

Publication Number Publication Date
TNSN97001A1 true TNSN97001A1 (en) 2005-03-15

Family

ID=20400947

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN97001A TNSN97001A1 (en) 1996-01-05 1997-01-03 CONTROLLED RELEASE PHARMACEUTICAL PEARLS CONTAINING FUROSEMIDE, AND A COMPOSITION MADE WITH SAID PEARLS.

Country Status (7)

Country Link
AU (1) AU1323897A (en)
HR (1) HRP970004A2 (en)
MA (1) MA26416A1 (en)
SE (1) SE9600046D0 (en)
TN (1) TNSN97001A1 (en)
WO (1) WO1997025028A1 (en)
ZA (1) ZA9610888B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070051953A (en) 1998-11-02 2007-05-18 엘란 코포레이션, 피엘씨 Multiparticulate modified release composition
FR2796840B1 (en) 1999-07-26 2003-06-20 Ethypharm Lab Prod Ethiques LOW-DOSE TABLETS AND METHOD OF PREPARATION
HU230828B1 (en) 1999-10-29 2018-08-28 Euro Celtique Sa Controlled release hydrocodone formulations
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
CN101317825A (en) 2000-10-30 2008-12-10 欧罗赛铁克股份有限公司 Controlled release hydrocodone formulations
US20030091633A1 (en) * 2001-11-15 2003-05-15 John Kelly Methods and compositions for use of (S)-bisoprolol
IL160095A0 (en) * 2004-01-28 2004-06-20 Yissum Res Dev Co Formulations for poorly soluble drugs
EP1669074B1 (en) * 2004-12-01 2010-06-02 Par Pharmaceuticals, Inc. Use of megestrol acetate for improving heart function and the treatment of heart insufficiency
WO2009145716A1 (en) * 2008-05-28 2009-12-03 Astrazeneca Ab New pharmaceutical formulation useful in gerd therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
US4938968A (en) * 1988-07-26 1990-07-03 Norjec Development Associates, Inc. Controlled release indomethacin
CA1338596C (en) * 1988-09-27 1996-09-17 Hiroyoshi Koyama Granules having core and their production

Also Published As

Publication number Publication date
SE9600046D0 (en) 1996-01-05
WO1997025028A1 (en) 1997-07-17
HRP970004A2 (en) 1998-04-30
AU1323897A (en) 1997-08-01
MA26416A1 (en) 2004-12-20
ZA9610888B (en) 1997-07-07

Similar Documents

Publication Publication Date Title
EP0164669B1 (en) Process for coating pharmaceutical forms
Yuan et al. Flow modulates coronary venular permeability by a nitric oxide-related mechanism
TNSN98009A1 (en) PHARMACEUTICAL COMPOSITION OF FENOFIBRATE WITH HIGH BIODAVAILABILITY AND PROCESS FOR PREPARING THE SAME
US3656997A (en) Coated gelatin capsules and process for producing same
PT64840B (en) PROCESS FOR THE PREPARATION OF ARALQUILIC ESTERS OF 1,4-DIHYDRAPIRIDINOCARBOXILIC ACID WITH CORONARY AND ANTIHYPERTENSIVE EFFECT APPLICATION OF THE SAME FOR THE PREPARATION OF CORONARY AND ANTIHYPERTENSIVE PHARMACEUTICAL COMPOSITIONS AND APPLICATION OF SAID PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF BLOOD LACIRCULATION DISEASES
DE69817008T2 (en) LOW TEMPERATURE LAYERS
EP0035780B1 (en) Coating compositions for enterosoluble solid dosage forms
TNSN97001A1 (en) CONTROLLED RELEASE PHARMACEUTICAL PEARLS CONTAINING FUROSEMIDE, AND A COMPOSITION MADE WITH SAID PEARLS.
EP1467724B1 (en) Orodispersible pharmaceutical composition comprising agomelatine
FR2576786A1 (en) PROCESS FOR TREATING DOSAGE FORMS
HU211544A9 (en) Transdermal composition
FR2569107A1 (en) LONG-TERM ADHESIVE ANTIFUNGAL SUPPOSITORIES
US4150110A (en) Coated granules of polyacrylic alkali metal salts and method of producing same
CA2330500A1 (en) Pharmaceutical compositions capable of being gelled
DE2012775A1 (en) Ointment foils and processes for their manufacture
FR2596991A1 (en) LIQUID MEDICINE FOR THE TREATMENT OF PSORIASIS, BASED ON FILM-FORMING POLYMERS
DE69535305T2 (en) MEANS TO REDUCE MOLECULAR FUNCTIONS
DE2135073A1 (en) Dissolvable pharmaceutical capsule - formed by polymerizing vinylic monomer
DE1492156A1 (en) Water-soluble shellac for coating solid medicinal preparations for oral administration
DE2741755C2 (en) Polymer-based coating compositions for biologically active preparations, processes for their production and biologically active preparations coated with these coating compositions and processes for producing the same
DE3800256A1 (en) BIOADHAESIVE SUPPOSITORIES
BE897221A (en) LONG-TERM PRODUCTS CONTAINING SULOCTIDIL
DE1467855A1 (en) Rectal capsule coatings and a process for their production
EP0250578A1 (en) Process for producing shapes for administering individual doses and shapes thus produced.
EP0208213A1 (en) Envelope for pharmaceutical compositions